Last edition
News about Market
Anbenitamab Set to Lead as First Bispecific mAb in China's HER2+ Gastric Cancer Market: GlobalData
China’s NMPA has accepted Alphamab Oncology’s NDA for KN026 (Anbenitamab), which could become the first bispecific mAb for HER2-positive gastric and GEJ cancer, according to GlobalData.
Market | 25/09/2025 | By Dineshwori | 358
Vidal Health and SII Collaborate on HPV Vaccine Access
Vidal Health and Serum Institute of India (SII) have partnered to boost cervical cancer prevention, launching from 1 October 2025 a first-of-its-kind cashless platform for HPV vaccination—covering digital bookings, consent, and certification with zero paperwork.
Market | 24/09/2025 | By Dineshwori | 139
Asia Pacific Leads Global Pharmaceutical Capsule Filling Machines Market
The Asia Pacific region dominated the global pharmaceutical capsule filling machines market in 2024, capturing a 40 percent share, according to a report by Precedence Research.
Market | 23/09/2025 | By Dineshwori | 216
Rubicon Research, a pharmaceutical formulations company, has announced that in a pre-IPO transaction, General Atlantic Singapore RR transferred 2.889 million equity shares to TIMF Holdings and 360 ONE funds at INR 484.47 per share, aggregating to INR 140 crore.
Market | 22/09/2025 | By Darshana | 644
Amber Implants Secures FDA 510(k) Clearance for VCFix Spinal System
The VCFix Spinal System, a novel treatment for vertebral compression fractures, has received FDA clearance following one-year trial results that confirmed its safety, performance, and significant clinical benefits. A US commercial pilot launch is planned for early 2026, with broader physician availability expected by summer 2026.
Market | 19/09/2025 | By Dineshwori | 233
Singapore fast-tracks medtech innovation with first regulatory reliance pilot: GlobalData
The six-month pilot of the Medical Device Regulatory Reliance Programme, running from 1 September, 2025 to 28 February, 2026, aims to expedite market access for Class B, C and D medical devices by reducing duplicate regulatory reviews and leveraging each other's approvals.
Market | 18/09/2025 | By Dineshwori | 170
VarmX and CSL Sign Deal Worth up to USD 2.2 Billion
Under the agreement, CSL will fully fund clinical development of VMX-C001 and pay VarmX shareholders USD 117 million upfront for an exclusive option to acquire VarmX, in a transaction worth up to USD 2.2 billion
Market | 17/09/2025 | By Dineshwori | 206
ExSight Ventures Invests in RevOpsis Therapeutics to Develop Eye Disease Therapies
RevOpsis is developing a novel class of multi-specific antibody-based treatments designed to address significant unmet needs in ophthalmology, with an initial focus on wet Age-related Macular Degeneration (AMD) and diabetic eye disease.
Market | 17/09/2025 | By Dineshwori | 190
Sanguine Expands Oncology Biospecimen Access via Clinic Partnerships
Through these partnerships, Sanguine now offers researchers access to a growing inventory of oncology biospecimens, including blood, plasma, serum and peripheral blood mononuclear cells (PBMCs), collected using minimally invasive methods to reduce donor burden and accelerate study timelines.
Market | 17/09/2025 | By Dineshwori | 131
Ocugen and Kwangdong Finalise OCU400 Gene Therapy Deal for Retinitis Pigmentosa in Korea
Pursuant to the licence agreement, Ocugen will receive upfront license fees and near-term development milestones equaling up to USD 7.5 million. The company will be entitled to sales milestones of USD 1.5 million for every USD 15 million of sales in Korea, projected to reach USD 180 million or more in the first 10 years of commercialisation.
Market | 17/09/2025 | By Dineshwori | 577
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy